Clostridium butyricum
Clostridium
Botulinum Toxins
Plasmalogens
Clostridium botulinum
Botulism
Propylene Glycols
Clostridium difficile
Fermentation
Glycerol
Encyclopedias as Topic
Peer Review, Research
Japan
Batch and fed-batch production of butyric acid by clostridium butyricum ZJUCB. (1/22)
The production of butyric acid by Clostridium butyricum ZJUCB at various pH values was investigated. In order to study the effect of pH on cell growth, butyric acid biosynthesis and reducing sugar consumption, different cultivation pH values ranging from 6.0 to 7.5 were evaluated in 5-L bioreactor. In controlled pH batch fermentation, the optimum pH for cell growth and butyric acid production was 6.5 with a cell yield of 3.65 g/L and butyric acid yield of 12.25 g/L. Based on these results, this study then compared batch and fed-batch fermentation of butyric acid production at pH 6.5. Maximum value (16.74 g/L) of butyric acid concentration was obtained in fed-batch fermentation compared to 12.25 g/L in batch fermentation. It was concluded that cultivation under fed-batch fermentation mode could enhance butyric acid production significantly (P<0.01) by C. butyricum ZJUCB. (+info)Microbial conversion of glycerol to 1,3-propanediol: physiological comparison of a natural producer, Clostridium butyricum VPI 3266, and an engineered strain, Clostridium acetobutylicum DG1(pSPD5). (2/22)
Clostridium acetobutylicum is not able to grow on glycerol as the sole carbon source since it cannot reoxidize the excess of NADH generated by glycerol catabolism. Nevertheless, when the pSPD5 plasmid, carrying the NADH-consuming 1,3-propanediol pathway from C. butyricum VPI 3266, was introduced into C. acetobutylicum DG1, growth on glycerol was achieved, and 1,3-propanediol was produced. In order to compare the physiological behavior of the recombinant C. acetobutylicum DG1(pSPD5) strain with that of the natural 1,3-propanediol producer C. butyricum VPI 3266, both strains were grown in chemostat cultures with glycerol as the sole carbon source. The same "global behavior" was observed for both strains: 1,3-propanediol was the main fermentation product, and the qH2 flux was very low. However, when looking at key intracellular enzyme levels, significant differences were observed. Firstly, the pathway for glycerol oxidation was different: C. butyricum uses a glycerol dehydrogenase and a dihydroxyacetone kinase, while C. acetobutylicum uses a glycerol kinase and a glycerol-3-phosphate dehydrogenase. Secondly, the electron flow is differentially regulated: (i) in C. butyricum VPI 3266, the in vitro hydrogenase activity is 10-fold lower than that in C. acetobutylicum DG1(pSPD5), and (ii) while the ferredoxin-NAD+ reductase activity is high and the NADH-ferredoxin reductase activity is low in C. acetobutylicum DG1(pSPD5), the reverse is observed for C. butyricum VPI 3266. Thirdly, lactate dehydrogenase activity is only detected in the C. acetobutylicum DG1(pSPD5) culture, explaining why this microorganism produces lactate. (+info)Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy. (3/22)
AIM: To investigate the effect of probiotic bacterium, Clostridium butyricum MIYAIRI 588 strain (CBM) on the changes of the fecal flora in Helicobacter pylori (H. pylori) treatment. METHODS: Thirty-five patients with gastric or duodenal ulcers positive for H. pylori were randomized either to 1 wk amoxicillin, clarithromycin, lansoprazole (Group 1) or to the same regimen supplemented with CBM 7 d ahead of the triple therapy (Group 2). Stool samples were collected before and 2, 4, 7, 15, and 22 d after the starting eradication therapy, and were examined intestinal flora. Patients were required to keep a diary record of their condition. RESULTS: Obligate anaerobes decreased significantly on d 2, 4, 8 and 15 in Group 1. On the other hand, they did not decrease significantly in Group 2. The Escherichia coli was dominant bacterium in Enterobacteriaceae, but that was replaced by other species such as Klebsiella and Enterobacter after eradication in Group 1. The change was suppressed in Group 2. Abdominal symptoms were less frequent in Group 2 than in Group 1. CONCLUSION: The combined use of CBM reduced the changes in the intestinal flora and decreased the incidence of gastrointestinal side effects. (+info)Effects of dietary supplementation with clostridium butyricum on the growth performance and humoral immune response in Miichthys miiuy. (4/22)
The effects of dietary supplementation with Clostridium butyricum on growth performance and humoral immune response in Miichthys miiuy were evaluated. One hundred and fifty Miichthys miiuy weighing approximately 200-260 g were divided into five groups and reared in 15 tanks with closed circuiting culture system. The animals were fed 5 diets: basal diet only (control) or supplemented of the basal diet with C. butyricum at doses of 10(3) (CB1), 10(5) (CB2), 10(7) (CB3) or 10(9) (CB4) CFU/g. Compared with the control, the serum phenoloxidase activity was significantly increased by the supplementation (P<0.05), acid phosphatases activity was increased significantly (P<0.05) at the doses of 10(9) CFU/g. Serum lysozyme activity peaked at dose of 10(7) CFU/g and in the skin mucus at dose of 10(9) CFU/g. Immunoglobulin M level in the serum and skin mucus was increased except at dose of 10(3) CFU/g (P<0.05). The growth at the dose of 10(9) CFU/g was higher than that of the control (P<0.05). It is concluded that supplementation of C. butyricum can mediate the humoral immune responses and improve the growth performance in Miichthys miiuy. (+info)Clostridium butyricum sepsis in an injection drug user with an indwelling central venous catheter. (5/22)
(+info)Ability of Lactobacillus fermentum to overcome host alpha-galactosidase deficiency, as evidenced by reduction of hydrogen excretion in rats consuming soya alpha-galacto-oligosaccharides. (6/22)
(+info)Effects of active egg white product/ Clostridium butyricum Miyairi 588 additive on peripheral leukocyte populations in periparturient dairy cows. (7/22)
The leukocyte populations of periparturient dairy cows were analyzed after administration of active egg white/Clostridium butyricum Miyairi additive. Sixty-eight Holstein milking cows were divided into 3 groups. Group A was administered active egg white product (AEWP)/Clostridium butyricum Miyairi 588 (Miyairi 588) additive (n=23). Group B was administered Miyairi 588 only (n=23), and Group C was the control group (n=22). The challenged groups were administered 100 g of AEWP + Miyairi 588, or Miyairi 588 alone, daily for 60 days from 1 month before until 1 month after paturition. Blood samples were collected from all groups three times (1 month before, 1 week after and 1 month after parturition) for analysis of the peripheral leukocyte population. The results showed significantly higher numbers of CD4+ cells in Group A compared with Group C 1 week after paturition. AEWP/Miyairi 588 additive may enhance the number of CD4+ T cells in periparturient dairy cows. (+info)Microbial conversion of glycerol to 1,3-propanediol by an engineered strain of Escherichia coli. (8/22)
(+info)'Clostridium butyricum' is a gram-positive, spore-forming, rod-shaped bacterium that is commonly found in the environment, including soil and water. It is also part of the normal gut microbiota in humans and animals. This organism produces butyric acid as one of its main fermentation products, hence the name 'butyricum'.
While 'Clostridium butyricum' can sometimes be associated with human diseases, particularly in individuals with weakened immune systems or underlying gastrointestinal disorders, it is also being investigated for its potential probiotic properties. Some studies suggest that certain strains of this bacterium may help prevent and treat various conditions, such as antibiotic-associated diarrhea, irritable bowel syndrome, and inflammatory bowel disease. However, more research is needed to confirm these findings and establish the safety and efficacy of 'Clostridium butyricum' as a probiotic.
'Clostridium' is a genus of gram-positive, rod-shaped bacteria that are widely distributed in nature, including in soil, water, and the gastrointestinal tracts of animals and humans. Many species of Clostridium are anaerobic, meaning they can grow and reproduce in environments with little or no oxygen. Some species of Clostridium are capable of producing toxins that can cause serious and sometimes life-threatening illnesses in humans and animals.
Some notable species of Clostridium include:
* Clostridium tetani, which causes tetanus (also known as lockjaw)
* Clostridium botulinum, which produces botulinum toxin, the most potent neurotoxin known and the cause of botulism
* Clostridium difficile, which can cause severe diarrhea and colitis, particularly in people who have recently taken antibiotics
* Clostridium perfringens, which can cause food poisoning and gas gangrene.
It is important to note that not all species of Clostridium are harmful, and some are even beneficial, such as those used in the production of certain fermented foods like sauerkraut and natto. However, due to their ability to produce toxins and cause illness, it is important to handle and dispose of materials contaminated with Clostridium species carefully, especially in healthcare settings.
Botulinum toxins are neurotoxic proteins produced by the bacterium Clostridium botulinum and related species. They are the most potent naturally occurring toxins, and are responsible for the paralytic illness known as botulism. There are seven distinct botulinum toxin serotypes (A-G), each of which targets specific proteins in the nervous system, leading to inhibition of neurotransmitter release and subsequent muscle paralysis.
In clinical settings, botulinum toxins have been used for therapeutic purposes due to their ability to cause temporary muscle relaxation. Botulinum toxin type A (Botox) is the most commonly used serotype in medical treatments, including management of dystonias, spasticity, migraines, and certain neurological disorders. Additionally, botulinum toxins are widely employed in aesthetic medicine for reducing wrinkles and fine lines by temporarily paralyzing facial muscles.
It is important to note that while botulinum toxins have therapeutic benefits when used appropriately, they can also pose significant health risks if misused or improperly handled. Proper medical training and supervision are essential for safe and effective utilization of these powerful toxins.
Plasmalogens are a type of complex lipid called glycerophospholipids, which are essential components of cell membranes. They are characterized by having a unique chemical structure that includes a vinyl ether bond at the sn-1 position of the glycerol backbone and an ester bond at the sn-2 position, with the majority of them containing polyunsaturated fatty acids. The headgroup attached to the sn-3 position is typically choline or ethanolamine.
Plasmalogens are abundant in certain tissues, such as the brain, heart, and skeletal muscle. They have been suggested to play important roles in cellular functions, including membrane fluidity, signal transduction, and protection against oxidative stress. Reduced levels of plasmalogens have been associated with various diseases, including neurological disorders, cardiovascular diseases, and aging-related conditions.
'Clostridium botulinum' is a gram-positive, rod-shaped, anaerobic bacteria that produces one or more neurotoxins known as botulinum toxins. These toxins are among the most potent naturally occurring biological poisons and can cause a severe form of food poisoning called botulism in humans and animals. Botulism is characterized by symmetrical descending flaccid paralysis, which can lead to respiratory and cardiovascular failure, and ultimately death if not treated promptly.
The bacteria are widely distributed in nature, particularly in soil, sediments, and the intestinal tracts of some animals. They can form spores that are highly resistant to heat, chemicals, and other environmental stresses, allowing them to survive for long periods in adverse conditions. The spores can germinate and produce vegetative cells and toxins when they encounter favorable conditions, such as anaerobic environments with appropriate nutrients.
Human botulism can occur through three main routes of exposure: foodborne, wound, and infant botulism. Foodborne botulism results from consuming contaminated food containing preformed toxins, while wound botulism occurs when the bacteria infect a wound and produce toxins in situ. Infant botulism is caused by the ingestion of spores that colonize the intestines and produce toxins, mainly affecting infants under one year of age.
Prevention measures include proper food handling, storage, and preparation practices, such as cooking and canning foods at appropriate temperatures and for sufficient durations. Wound care and prompt medical attention are crucial in preventing wound botulism. Vaccines and antitoxins are available for prophylaxis and treatment of botulism in high-risk individuals or in cases of confirmed exposure.
Botulism is a rare but serious condition caused by the toxin produced by the bacterium Clostridium botulinum. The neurotoxin causes muscle paralysis, which can lead to respiratory failure and death if not treated promptly. Botulism can occur in three main forms: foodborne, wound, and infant.
Foodborne botulism is caused by consuming contaminated food, usually home-canned or fermented foods with low acid content. Wound botulism occurs when the bacterium infects a wound and produces toxin in the body. Infant botulism affects babies under one year of age who have ingested spores of the bacterium, which then colonize the intestines and produce toxin.
Symptoms of botulism include double vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, muscle weakness, and paralysis that progresses downward from the head to the limbs. Treatment typically involves supportive care such as mechanical ventilation, intensive care unit monitoring, and antitoxin therapy. Prevention measures include proper food handling and canning techniques, prompt wound care, and avoiding consumption of known sources of contaminated food.
Propylene glycol is not a medical term, but rather a chemical compound. Medically, it is classified as a humectant, which means it helps retain moisture. It is used in various pharmaceutical and cosmetic products as a solvent, preservative, and moisturizer. In medical settings, it can be found in topical creams, oral and injectable medications, and intravenous (IV) fluids.
The chemical definition of propylene glycol is:
Propylene glycol (IUPAC name: propan-1,2-diol) is a synthetic organic compound with the formula CH3CH(OH)CH2OH. It is a viscous, colorless, and nearly odorless liquid that is miscible with water, acetone, and chloroform. Propylene glycol is used as an antifreeze when mixed with water, as a solvent in the production of polymers, and as a moisturizer in various pharmaceutical and cosmetic products. It has a sweet taste and is considered generally recognized as safe (GRAS) by the U.S. Food and Drug Administration (FDA) for use as a food additive.
'Clostridium difficile' (also known as 'C. difficile' or 'C. diff') is a type of Gram-positive, spore-forming bacterium that can be found in the environment, including in soil, water, and human and animal feces. It is a common cause of healthcare-associated infections, particularly in individuals who have recently received antibiotics or have other underlying health conditions that weaken their immune system.
C. difficile produces toxins that can cause a range of symptoms, from mild diarrhea to severe colitis (inflammation of the colon) and potentially life-threatening complications such as sepsis and toxic megacolon. The most common toxins produced by C. difficile are called TcdA and TcdB, which damage the lining of the intestine and cause inflammation.
C. difficile infections (CDIs) can be difficult to treat, particularly in severe cases or in patients who have recurrent infections. Treatment typically involves discontinuing any unnecessary antibiotics, if possible, and administering specific antibiotics that are effective against C. difficile, such as metronidazole, vancomycin, or fidaxomicin. In some cases, fecal microbiota transplantation (FMT) may be recommended as a last resort for patients with recurrent or severe CDIs who have not responded to other treatments.
Preventing the spread of C. difficile is critical in healthcare settings, and includes measures such as hand hygiene, contact precautions, environmental cleaning, and antibiotic stewardship programs that promote the appropriate use of antibiotics.
Fermentation is a metabolic process in which an organism converts carbohydrates into alcohol or organic acids using enzymes. In the absence of oxygen, certain bacteria, yeasts, and fungi convert sugars into carbon dioxide, hydrogen, and various end products, such as alcohol, lactic acid, or acetic acid. This process is commonly used in food production, such as in making bread, wine, and beer, as well as in industrial applications for the production of biofuels and chemicals.
Clostridium infections are caused by bacteria of the genus Clostridium, which are gram-positive, rod-shaped, spore-forming, and often anaerobic organisms. These bacteria can be found in various environments, including soil, water, and the human gastrointestinal tract. Some Clostridium species can cause severe and potentially life-threatening infections in humans. Here are some of the most common Clostridium infections with their medical definitions:
1. Clostridioides difficile infection (CDI): An infection caused by the bacterium Clostridioides difficile, previously known as Clostridium difficile. It typically occurs after antibiotic use disrupts the normal gut microbiota, allowing C. difficile to overgrow and produce toxins that cause diarrhea, colitis, and other gastrointestinal symptoms. Severe cases can lead to sepsis, toxic megacolon, or even death.
2. Clostridium tetani infection: Also known as tetanus, this infection is caused by the bacterium Clostridium tetani. The spores of this bacterium are commonly found in soil and animal feces. They can enter the body through wounds, cuts, or punctures, germinate, and produce a potent exotoxin called tetanospasmin. This toxin causes muscle stiffness and spasms, particularly in the neck and jaw (lockjaw), which can lead to difficulty swallowing, breathing, and potentially fatal complications.
3. Clostridium botulinum infection: This infection is caused by the bacterium Clostridium botulinum and results in botulism, a rare but severe paralytic illness. The bacteria produce neurotoxins (botulinum toxins) that affect the nervous system, causing symptoms such as double vision, drooping eyelids, slurred speech, difficulty swallowing, dry mouth, and muscle weakness. In severe cases, botulism can lead to respiratory failure and death.
4. Gas gangrene (Clostridium perfringens infection): A rapidly progressing soft tissue infection caused by Clostridium perfringens or other clostridial species. The bacteria produce potent exotoxins that cause tissue destruction, gas production, and widespread necrosis. Gas gangrene is characterized by severe pain, swelling, discoloration, and a foul-smelling discharge. If left untreated, it can lead to sepsis, multi-organ failure, and death.
5. Clostridioides difficile infection (C. difficile infection): Although not caused by a typical clostridial species, C. difficile is a gram-positive, spore-forming bacterium that can cause severe diarrhea and colitis, particularly in hospitalized patients or those who have recently taken antibiotics. The bacteria produce toxins A and B, which damage the intestinal lining and contribute to inflammation and diarrhea. C. difficile infection can range from mild to life-threatening, with complications such as sepsis, toxic megacolon, and bowel perforation.
Glycerol, also known as glycerine or glycerin, is a simple polyol (a sugar alcohol) with a sweet taste and a thick, syrupy consistency. It is a colorless, odorless, viscous liquid that is slightly soluble in water and freely miscible with ethanol and ether.
In the medical field, glycerol is often used as a medication or supplement. It can be used as a laxative to treat constipation, as a source of calories and energy for people who cannot eat by mouth, and as a way to prevent dehydration in people with certain medical conditions.
Glycerol is also used in the production of various medical products, such as medications, skin care products, and vaccines. It acts as a humectant, which means it helps to keep things moist, and it can also be used as a solvent or preservative.
In addition to its medical uses, glycerol is also widely used in the food industry as a sweetener, thickening agent, and moisture-retaining agent. It is generally recognized as safe (GRAS) by the U.S. Food and Drug Administration (FDA).
An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.
Peer review in the context of research refers to the evaluation of scientific, academic, or professional work by others working in the same field. The purpose of peer review is to ensure that the research is rigorous, valid, and relevant to the field. In a peer-review process, experts in the relevant field assess the research article, report, or other type of scholarly work for its accuracy, quality, and significance before it is published or presented at a conference.
The peer-review process typically involves several stages:
1. Submission: The author(s) submit their manuscript to a journal, conference, or other publication venue.
2. Assignment: The editor of the publication assigns the manuscript to one or more reviewers who are experts in the field.
3. Review: The reviewers evaluate the manuscript based on criteria such as originality, methodology, data analysis, interpretation of results, and contribution to the field. They provide feedback and recommendations to the editor.
4. Decision: Based on the feedback from the reviewers, the editor makes a decision about whether to accept, reject, or request revisions to the manuscript.
5. Revision: If the manuscript is rejected or requires revisions, the author(s) may have an opportunity to revise and resubmit the manuscript for further consideration.
Peer review is a critical component of the scientific process, as it helps ensure that research is held to high standards of quality and integrity. It also provides a mechanism for identifying and correcting errors or weaknesses in research before it is published or disseminated widely.
I'm sorry for any confusion, but "Japan" is not a medical term. Japan is the name of a country, officially known as Nippon-koku or Nihon-koku in Japanese, and is located in East Asia. It is an island nation in the Pacific Ocean with a population of about 126 million people.
If you have any medical questions or terms that you would like me to define, please let me know!
Pharmaceutical preparations refer to the various forms of medicines that are produced by pharmaceutical companies, which are intended for therapeutic or prophylactic use. These preparations consist of an active ingredient (the drug) combined with excipients (inactive ingredients) in a specific formulation and dosage form.
The active ingredient is the substance that has a therapeutic effect on the body, while the excipients are added to improve the stability, palatability, bioavailability, or administration of the drug. Examples of pharmaceutical preparations include tablets, capsules, solutions, suspensions, emulsions, ointments, creams, and injections.
The production of pharmaceutical preparations involves a series of steps that ensure the quality, safety, and efficacy of the final product. These steps include the selection and testing of raw materials, formulation development, manufacturing, packaging, labeling, and storage. Each step is governed by strict regulations and guidelines to ensure that the final product meets the required standards for use in medical practice.